Eberhard Schleyer

2.6k total citations
69 papers, 1.8k citations indexed

About

Eberhard Schleyer is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Eberhard Schleyer has authored 69 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 22 papers in Genetics and 22 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Eberhard Schleyer's work include Acute Lymphoblastic Leukemia research (20 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Myeloid Leukemia Research (19 papers). Eberhard Schleyer is often cited by papers focused on Acute Lymphoblastic Leukemia research (20 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Myeloid Leukemia Research (19 papers). Eberhard Schleyer collaborates with scholars based in Germany, United Kingdom and United States. Eberhard Schleyer's co-authors include Gerhard Ehninger, Martin Bornhäuser, Stefan Pursche, Thomas Illmer, Malte von Bonin, Wolfgang Kern, Wolfgang Hiddemann, Jens Freiberg‐Richter, Andreas Jenke and Michael Unterhalt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Eberhard Schleyer

68 papers receiving 1.8k citations

Peers

Eberhard Schleyer
Fitzroy W. Dawkins United States
Ehab Atallah United States
Suning Chen China
R S Walters United States
Michael Medinger Switzerland
Noppadol Siritanaratkul Thailand
Marie‐Hélène Schlageter France
Roger Chen United States
Hong‐Hu Zhu China
Evans We United States
Fitzroy W. Dawkins United States
Eberhard Schleyer
Citations per year, relative to Eberhard Schleyer Eberhard Schleyer (= 1×) peers Fitzroy W. Dawkins

Countries citing papers authored by Eberhard Schleyer

Since Specialization
Citations

This map shows the geographic impact of Eberhard Schleyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eberhard Schleyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eberhard Schleyer more than expected).

Fields of papers citing papers by Eberhard Schleyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eberhard Schleyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eberhard Schleyer. The network helps show where Eberhard Schleyer may publish in the future.

Co-authorship network of co-authors of Eberhard Schleyer

This figure shows the co-authorship network connecting the top 25 collaborators of Eberhard Schleyer. A scholar is included among the top collaborators of Eberhard Schleyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eberhard Schleyer. Eberhard Schleyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lang, Fabian, Lydia Wunderle, Eberhard Schleyer, et al.. (2020). A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology. 21(1). 70–70. 28 indexed citations
2.
Treiber, Gerhard, et al.. (2008). Imatinib for hepatocellular cancer – Focus on pharmacokinetic/pharmacodynamic modelling and liver function. Cancer Letters. 260(1-2). 146–154. 21 indexed citations
3.
Freiberg‐Richter, Jens, Uwe Platzbecker, Alexander Kiani, et al.. (2008). Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplantation. 42(2). 113–120. 31 indexed citations
4.
Dresemann, G., Mark Rosenthal, Klaus Hoeffken, et al.. (2007). Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - An international open label randomised phase III study (ambrosia-study). Neuro-Oncology. 9(4). 2 indexed citations
5.
Kroschinsky, Frank, Juliane Mueller, Stefan Pursche, et al.. (2007). Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Cancer Chemotherapy and Pharmacology. 61(5). 785–790. 10 indexed citations
6.
Fierro, Fernando A., Thomas Illmer, Duohui Jing, et al.. (2007). Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Proliferation. 40(3). 355–366. 78 indexed citations
7.
Said, Samir M., Judit Háhn, Eberhard Schleyer, et al.. (2006). Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia. Clinical Research in Cardiology. 96(2). 61–69. 35 indexed citations
8.
Jenke, Andreas, et al.. (2004). Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis. Journal of Chromatography B. 805(1). 147–153. 10 indexed citations
9.
Waßmann, Barbara, Urban Scheuring, Christian Thiede, et al.. (2003). Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplantation. 31(7). 611–614. 6 indexed citations
10.
Schleyer, Eberhard, Stefan Pursche, C.-H. Köhne, et al.. (2003). Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. Journal of Chromatography B. 799(1). 23–36. 40 indexed citations
11.
Coutre, Philipp le, Karl‐Anton Kreuzer, Stefan Pursche, et al.. (2003). Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemotherapy and Pharmacology. 53(4). 313–323. 134 indexed citations
12.
Schleyer, Eberhard, K. Lenhard Rudolph, Michael Unterhalt, et al.. (2000). Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid. Cancer Chemotherapy and Pharmacology. 45(2). 165–171. 1 indexed citations
13.
Kern, Wolfgang, Jan Braess, Hartmut Bertz, et al.. (1998). Chronic systemic aspergillosis in a patient with acute myeloid leukemia. Annals of Hematology. 76(3-4). 175–177. 2 indexed citations
14.
Kern, Wolfgang, Eberhard Schleyer, Michael Unterhalt, et al.. (1997). High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Cancer. 79(1). 59–68. 1 indexed citations
15.
16.
Braess, Jan, et al.. (1996). Detection and determination of the major metabolites of [3H]cytosine arabinoside by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 676(1). 131–140. 19 indexed citations
17.
Gralow, I., et al.. (1995). Kontinuierliche subkutane Buprenorphinapplikation in der Therapie karzinombedingter Schmerzen. Der Schmerz. 9(3). 117–123. 2 indexed citations
18.
Gralow, I., et al.. (1995). Pharmakokinetik des Buprenorphins bei subkutaner Applikation. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. 30(7). 412–416. 5 indexed citations
19.
Schleyer, Eberhard, Rainer Lohmann, Clyde N. Rolf, et al.. (1993). Column-switching solid-phase trace-enrichment high-performance liquid chromatographic method for measurement of buprenorphine and norbuprenorphine in human plasma and urine by electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 614(2). 275–283. 25 indexed citations
20.
Schleyer, Eberhard, et al.. (1992). Pharmacokinetics and protein binding of leucovorin diastereomers. 33. 532. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fitzroy W. Dawkins Breakdown of academic impact, for papers by Ehab Atallah Breakdown of academic impact, for papers by Suning Chen Breakdown of academic impact, for papers by R S Walters Breakdown of academic impact, for papers by Michael Medinger Breakdown of academic impact, for papers by Noppadol Siritanaratkul Breakdown of academic impact, for papers by Marie‐Hélène Schlageter Breakdown of academic impact, for papers by Roger Chen Breakdown of academic impact, for papers by Hong‐Hu Zhu Breakdown of academic impact, for papers by Evans We
Rankless by CCL
2026